Read by QxMD icon Read

Myeloma multiple 2016

Hai-Min Chen, Wei Wei, Rong Peng, Hao-Tian Shi, Xiao-Ling Chen, Li-Xia Wu, Nian Zhou, Fan Zhou
OBJECTIVE: To evaluate the prognostic value of R-ISS staging system in patients with newly diagnosed multiple myeloma (NDMM). METHODS: The Chinical data of 412 patients with NDMM in our hospital from May 2010 to May 2016 were retrospectively analyzed. All the patients received conventional chemotherapy or thalidomide or bortezomib-based chemotherapy. All the patients with NDMM were divided into R-ISS-Ⅰ, R-ISS-Ⅱ and R-ISS-Ⅲ groups according to R-ISS staging system on the basis of ISS staging system, cytogenetics and LDH level...
February 2019: Zhongguo Shi Yan Xue Ye Xue za Zhi
Jin Zhang, Jie Yang, Pan-Pan Wang, Peng-Peng Zhang, Mao-Wen Yuan, Zhuan-Zhen Ma, Qi Zhou, Tong Wei, Xia-Li Mao, Ming Li, Long Zhao, Hao Zhang, Ya-Ming Xi
OBJECTIVE: To investigate the serum calcium level in 86 patients with newly diagnosed multiple myeloma (MM) and its correlation with clinical features. METHODS: The clinical data of 86 patients with newly diagnosed multiple myeloma in our hospital from 2009 to 2016 were retrospectively analyed. Clinical data of sex, age, hemoglobin, albumin, globulin, creatinine, uric acid, serum phosphorus, β2-microglobulin, immunophenotyping and disease staging were collected...
February 2019: Zhongguo Shi Yan Xue Ye Xue za Zhi
Robert M Rifkin, Rohan Medhekar, E Susan Amirian, Kathleen M Aguilar, Thomas Wilson, Marley Boyd, Khalid Mezzi, Sumeet Panjabi
Background: Most multiple myeloma (MM) patients ultimately progress, with remission duration decreasing after first relapse. Recently, novel agents have been approved for the treatment of relapsed MM. There is a paucity of real-world data on these treatments. We sought to compare time to next treatment (TTNT) in MM patients in their second line of therapy (LOT2), treated with common proteasome inhibitor (PI)-based triplets. Methods: Adult MM patients who received carfilzomib (K) between 1 November 2013 and 29 February 2016 at US Oncology Network (USON) clinics utilizing iKnowMed™ electronic health records (EHRs) were identified...
2019: Therapeutic Advances in Hematology
Morgan M Millar, Anita Y Kinney, Nicola J Camp, Lisa A Cannon-Albright, Mia Hashibe, David F Penson, Anne C Kirchhoff, Deborah W Neklason, Alicia W Gilsenan, Gretchen S Dieck, Antoinette M Stroup, Sandra L Edwards, Carrie Bateman, Marjorie E Carter, Carol Sweeney
When recruiting research participants through central cancer registries, high response fractions help ensure population-based representation. Using data from 17 recruitment efforts undertaken by the Utah Cancer Registry from 2007 to 2016, we conducted multivariable mixed effects logistic regression to identify case and study characteristics associated with making contact and obtaining cooperation of Utah cancer cases for the following studies: A Population-Based Childhood Cancer Survivor Cohort Study in Utah, Comparative Effectiveness Analysis of Surgery and Radiation for Prostate Cancer (CEASAR Study), Costs and Benefits of Follow-up Care for Adolescent and Young Adult Cancers, Genetic Analysis of Digestive Cancers, Genetic Epidemiology of Breast Cancer, Genetic Epidemiology of Chronic Lymphocytic Leukemia, Genetic Epidemiology of Multiple Myeloma, Head and Neck Cancer Susceptibility Genes, Impact of Remote Familial Colorectal Cancer Risk Assessment and Counseling (Family CARE Project), Medullary Thyroid Carcinoma (MTC) Surveillance Study Osteosarcoma Surveillance Study, the Prostate Cancer Outcomes Study, Risk Education & Assessment for Cancer Heredity Project (REACH Project), and the Utah Cancer Survivors Study...
January 25, 2019: American Journal of Epidemiology
Rikio Suzuki, Takayuki Warita, Yoshihiko Nakamura, Yuka Kitamura, Yasuyuki Aoyama, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando
A 67-year-old female was referred to our hospital with a sternal fracture in March 2008. She received a diagnosis of multiple myeloma (MM) BJP-κ type (ISS stage III). G-banding karyotype revealed 46, XX, t(11;22)(q23.3;q11.2) (Hubacek, Gene 592:193-9, 2016), which was later confirmed to be congenital. After repeated rounds of chemotherapy with bortezomib and lenalidomide, she obtained a very good partial response in August 2014, and she was followed up with no treatment. However, she relapsed in February 2016...
January 24, 2019: International Journal of Hematology
Mohd Nazri Hassan, Hafizuddin Mohamed Fauzi, Azlan Husin, Rapiaah Mustaffa, Rosline Hassan, Mohd Ismail Ibrahim, Noor Haslina Mohd Noor
Objectives: Autologous peripheral blood stem cells transplantation (APBSCT) is a therapeutic option which can be used in various hematological, neoplastic disorders including lymphoproliferative disease (LPD). Differences in patient populations and treatment modalities in different transplant centers mean it is important to improve the knowledge of the different factors affecting engraftment after APBSCT for the success of this procedure. We sought to determine the factors influencing neutrophil and platelet engraftment after APBSCT in patients with LPD...
January 2019: Oman Medical Journal
Anthony F Milano
BACKGROUND: -The values of SEER site recode variables are based on the primary site and histology data fields submitted to SEER by the registries. The site recode variables define the major cancer site/histology groups that are commonly used in the reporting of cancer incidence data and are added to the SEER databases as a convenience for researchers. These codes and definitions are periodically updated and changed by the National Cancer Institute as newer and more applicable information becomes available...
January 22, 2019: Journal of Insurance Medicine
Christopher Kim, Sumita Bhatta, Lori Cyprien, Rafael Fonseca, Rohini K Hernandez
Skeletal-related events (SREs) are common bone complications in multiple myeloma (MM). However, there are few real-world reports of their incidence. In this study, a database of oncology electronic health records was linked to administrative claims data. Patients identified were aged ≥18 years and newly diagnosed with MM, had ≥1 clinic visit within 1 month of diagnosis, and ≥1 year of follow-up after diagnosis. The study period was January 1, 2011 to December 31, 2016. 343 patients were included, 35% of whom had a baseline history of any SRE...
February 2019: Journal of Bone Oncology
Marie Joelle Jabagi, Norbert Vey, Anthony Goncalves, Thien Le Tri, Mahmoud Zureik, Rosemary Dray-Spira
Importance: Breast cancer survivors are at an increased risk of developing certain types of hematologic malignant neoplasm after diagnosis. Objective: To estimate the incidence of various types of hematologic malignant neoplasm in breast cancer survivors, both in absolute terms and in association with the general population. Design, Setting, and Participants: This nationwide cohort study conducted in France used data from the French National Health Data System, a database that contains all of French residents' health-related expenses...
January 4, 2019: JAMA network open
Mariam Youssef, Christine Arnesen, Cindy Arledge, Connie Langley, Danielle Sylvester, James Sikora, Marisa B Marques, X Long Zheng, Lance A Williams
BACKGROUND: Treatment of multiple myeloma with daratumumab (DARA) is increasing fast. Unfortunately, this antibody also attaches to red blood cells (RBCs) and mimics an autoantibody's panreactivity during pre-transfusion testing, necessitating specialized techniques, (e.g. dithiothreitol (DTT)) for alloantibody detection. Many hospitals use a reference lab for such testing, increasing both cost and turn-around time (TAT). Herein, we compare the cost and TAT, pre and post-implementation of an in-house DTT protocol...
January 6, 2019: Transfusion and Apheresis Science
Theodora Psaltopoulou, Theodoros N Sergentanis, Ioannis Ntanasis-Stathopoulos, Ioannis-Georgios Tzanninis, Elena Riza, Meletios A Dimopoulos
Overweight/obesity, adult attained height and physical activity are possible risk factors for hematological malignancies. This meta-analysis aims to evaluate the associations between these factors and hematological cancer risk in adults. Eligible cohort studies were sought in PubMed up to May 31, 2016; overall, 44 studies were included in the present analyses. Pooled relative risk (RR) estimates were calculated using random-effects models; separate analyses were conducted for non-Hodgkin lymphoma (NHL) and subtypes (diffuse large B-cell lymphoma, DLBCL; follicular cell lymphoma, FCL; small lymphocytic lymphoma/chronic lymphocytic leukemia, SLL/CLL), Hodgkin lymphoma (HL), multiple myeloma (MM), leukemia and subtypes (acute lymphoblastic leukemia, acute myeloid leukemia, AML)...
January 7, 2019: International Journal of Cancer. Journal International du Cancer
Hedwig M Blommestein, Chrissy H Y van Beurden-Tan, Margreet G Franken, Carin A Uyl-de Groot, Pieter Sonneveld, Sonja Zweegman
Decision making for not transplant eligible patients with multiple myeloma is complicated by lacking head-to-head comparisons of standards of care, increasing treatment modalities and rapidly evolving promising results of studies with novel regimens. To support evidence-based decision making, we performed a network meta-analysis for not transplant-eligible multiple myeloma patients that synthesizes direct and indirect evidence and enable a comparison of all treatments. Relevant randomized clinical trials were identified by a systematic literature review in EMBASE®, MEDLINE®, MEDLINE®-in-Process and the Cochrane Central Register of Controlled Trials for January-1999 to March-2016...
January 3, 2019: Haematologica
Nicolas H Hart, Daniel A Galvão, Christobel Saunders, Dennis R Taaffe, Kynan T Feeney, Nigel A Spry, Daphne Tsoi, Hilary Martin, Raphael Chee, Tim Clay, Andrew D Redfern, Robert U Newton
BACKGROUND: Skeletal metastases present a major challenge for clinicians, representing an advanced and typically incurable stage of cancer. Bone is also the most common location for metastatic breast carcinoma, with skeletal lesions identified in over 80% of patients with advanced breast cancer. Preclinical models have demonstrated the ability of mechanical stimulation to suppress tumour formation and promote skeletal preservation at bone sites with osteolytic lesions, generating modulatory interference of tumour-driven bone remodelling...
December 20, 2018: Trials
Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, Hartmut Goldschmidt, Vladimir Maisnar, Philippe Moreau, Chang Ki Min, Agnieszka Pluta, Wee-Joo Chng, Martin Kaiser, Sonja Zweegman, Maria-Victoria Mateos, Andrew Spencer, Shinsuke Iida, Gareth Morgan, Kaveri Suryanarayan, Zhaoyang Teng, Tomas Skacel, Antonio Palumbo, Ajeeta B Dash, Neeraj Gupta, Richard Labotka, S Vincent Rajkumar
BACKGROUND: Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT. METHODS: The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place in 167 clinical or hospital sites in 30 countries in Europe, the Middle East, Africa, Asia, and North and South America...
December 10, 2018: Lancet
Leah J McGrath, Rohini K Hernandez, Robert Overman, Diane Reams, Alexander Liede, M Alan Brookhart, Elizabeth O'Donnell
BACKGROUND: Prior to 2018, intravenous bisphosphonates (IV BPs) were the only therapies recommended to prevent skeletal-related events for patients diagnosed with multiple myeloma (MM). We examined patterns of IV BP initiation and interruption among patients with newly diagnosed MM (NDMM) in the United States. METHODS: Electronic health records linked to administrative health insurance claims were used to identify adults with NDMM between 1 January 2011 and 30 April 2016...
December 8, 2018: Cancer Medicine
Camila Peña, Christine Rojas, Hernán Rojas, Pablo Soto, Daniela Cardemil, Sandra Aranda, Carolina Contreras, Gabriel La Roca, Moisés Russo, Claudio Pérez, Vivianne Lois
BACKGROUND: Multiple myeloma (MM) is one of the most common malignancies found in hematology. AIM: To describe the features of patients with MM and perform a survival analysis according to the different treatment protocols used between 2000 and 2016. MATERIAL AND METHODS: Analysis of the database of the Chilean national anti-neoplastic drug program. Information was obtained from 1,103 patients, with a median age of 64.5 years (range 27-95) and a male to female ratio of 1:1...
July 2018: Revista Médica de Chile
Elisabet E Manasanch, Jatin J Shah, Hans C Lee, Donna M Weber, Sheeba K Thomas, Behrang Amini, Lei Feng, Zuzana Berkova, Michelle Hildebrandt, Robert Z Orlowski
BACKGROUND: Bortezomib with lenalidomide and dexamethasone (VRd) is a standard regimen for the front-line treatment of multiple myeloma. Panobinostat is approved in combination with bortezomib and dexamethasone in patients with myeloma who 'have been given at least two previous regimens including bortezomib and an immunomodulatory agent. We aimed to determine the maximum tolerated dose of a new regimen combining VRd with panobinostat in patients with newly diagnosed multiple myeloma. METHODS: In this phase 1 study, we enrolled patients from the University of Texas MD Anderson Cancer Center (Houston, TX, USA) with newly diagnosed multiple myeloma who were aged 18 years or older and eligible for autologous stem-cell transplant (ASCT) according to International Myeloma Working Group 2014 diagnostic criteria...
December 2018: Lancet Haematology
Mélanie Tia Weu, Cyr Guei Monlet, Amidou Sawadogo, Albert Coulibaly Pessa, Amelie Lagou Delphine, Apollinaire Gnionsahé Daze
BACKGROUND: Renal involvement is common during monoclonal gammopathies and their occurrence impacts the survival of the patients. Our objective was to describe the renal features during monoclonal gammopathies from 2004 to 2016 at the University Hospital of Yopougon in Abidjan. METHODS: Renal failure was defined as blood creatinine level > 20 mg/L and/or proteinuria > 500 mg/24 hours. RESULTS: We identified 42 cases of monoclonal gammopathiesincluding multiple myeloma (n=40) and monoclonal gammopathy of underdetermined significance (n=2)...
2018: Le Mali Médical
Nisha S Joseph, Jonathan L Kaufman, Lawrence H Boise, Kelly Valla, Dhwani K Almaula, Chikaodili O Obidike, Amelia A Langston, Edmund K Waller, Hanna J Khoury, Christopher R Flowers, Michael Graiser, Leonard T Heffner, Sagar Lonial, Ajay K Nooka
High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) are established components in the treatment of multiple myeloma; however, undergoing transplantation usually requires hematopoietic support, which poses a challenge among patients who are unwilling to receive blood products. Most transplant centers decline HDT/ASCT to these patients because of safety concerns. Here, the authors' institutional data on safety, engraftment parameters, and survival outcomes after bloodless ASCT (BL-ASCT) are examined among patients with myeloma...
January 15, 2019: Cancer
Praful Ravi, Shaji K Kumar, Lindsey Roeker, Wilson Gonsalves, Francis Buadi, Martha Q Lacy, Ronald S Go, Angela Dispenzieri, Prashant Kapoor, John A Lust, David Dingli, Yi Lin, Stephen J Russell, Nelson Leung, Morie A Gertz, Robert A Kyle, P Leif Bergsagel, S Vincent Rajkumar
The current definition of plasma cell leukemia (PCL)- ≥ 20% circulating plasma cells (CPCs) on peripheral smear and plasma cell count ≥ 2 × 109 /L-may be too stringent. We reviewed outcomes of 176 multiple myeloma (MM) patients diagnosed between 1971 and 2016, and who had CPCs detectable at diagnosis, to determine whether a lower threshold could be used to diagnose PCL. Median overall survival (mOS) was 1.1 years (95% CI 0.8-1.4) and was similar between patients with < 5% (n = 54, mOS = 1...
November 15, 2018: Blood Cancer Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"